semaglutide diabetes trial Positive results in testing #GLP-1 targeting #diabetes/#weight-loss medicine (Ozempic, Wegovy) in treatment-seeking patents with #alcohol use disorder (AUD) who were also obese. Alcohol consumed dropped over 70% after 26 weeks Trial design. Thick black arrows,

The SELECT trial, published in the New England Journal of Medicine in 2023, showed that semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease

CK-MB, creatine kinase isoenzyme-MB

A medium ear contains about 19 grams of carbohydrates, most of them as naturally occurring starch

GLP-1 operates through multiple mechanisms, including reducing hunger, increasing a sense of fullness after meals, boosting energy expenditure, and improving insulin sensitivity

Protein content was determined using Pierce BCA Protein Assay kit (Thermo Fisher Scientific)